Last reviewed · How we verify
OnabotulinumtoxinA 100 Units
At a glance
| Generic name | OnabotulinumtoxinA 100 Units |
|---|---|
| Also known as | BOTOX |
| Sponsor | Wake Forest University Health Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy (PHASE2, PHASE3)
- Silencing Neuroma Pain-Botulinum Toxin Versus Local Anesthetic Injection (NA)
- Reduced-dose Botox for Urgency Incontinence Among Elder Females (PHASE1, PHASE2)
- Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery (NA)
- OnabotulinumtoxinA for Trigeminal Neuralgia (PHASE4)
- Exoskeleton Robotic Assisted Gait Training in Spastic Stroke Post Botulinum Toxin A Injection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OnabotulinumtoxinA 100 Units CI brief — competitive landscape report
- OnabotulinumtoxinA 100 Units updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI